Showing results (141-150 of 168) with videos related to
Sort By:
Pageof 17
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 4, 2017
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI<sub>2</sub>) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) studyIoana R Preston, Richard N Channick, Kelly Chin, et al.Journal of Cardiovascular Pharmacology|January 28, 2003
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertensionVallerie V McLaughlin, Sean P Gaine, Robyn J Barst, et al.Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
Anatomical Variations in Pulmonary Arterial Branches in Patients Undergoing Evaluation for Chronic Thromboembolic Pulmonary HypertensionErinleigh Michaud, Michael Pan, Vladimir Lakhter, et al.Annals of the Rheumatic Diseases|October 25, 2017
Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohortCarina Mihai, Milos Antic, Rucsandra Dobrota, et al.Pulmonary Circulation|November 18, 2021
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertensionRobert P Frantz, Raymond L Benza, Richard N Channick, et al.The New England Journal of Medicine|December 25, 2015
Selexipag for the Treatment of Pulmonary Arterial HypertensionOlivier Sitbon, Richard Channick, Kelly M Chin, et al.The Lancet. Respiratory Medicine|October 18, 2016
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION studyMarius M Hoeper, Vallerie V McLaughlin, Joan Albert Barberá, et al.Arthritis Research & Therapy|December 11, 2014
Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT studyScott H Visovatti, Oliver Distler, J Gerry Coghlan, et al.Chest|June 6, 2021
Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-upKim M Kerr, C Greg Elliott, Kelly Chin, et al.Annals of the Rheumatic Diseases|January 1, 2017
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trialJohn Gerry Coghlan, Nazzareno Galiè, Joan Albert Barberà, et al.Pageof 17